Seminars in Respiratory and Critical Care Medicine, 2002 Lymphangioleiomyomatosis (LAM) is a rare disease categorized by an overgrowth of atypical smooth muscle cells (LAM cells) in the lungs and axial lymphatics, which is associated with the mesenchymal tumor angiomyolipoma. The disease occurs in women generally in their mid thirties with a prevalence approximately 1 per million in the general population ...
Simon R, Johnson, Anne E, Tattersfield
openaire +4 more sources
Anesthesia for Suboccipital Craniotomy in a Patient with Lymphangioleiomyomatosis: A Case Report [PDF]
, 2012 Lymphangioleiomyomatosis (LAM) is a rare pulmonary condition often presenting with spontaneous pneumothorax. Imaging or biopsy confirm the diagnosis.
Luman, Emily +2 more
core +3 more sources
Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study [PDF]
, 2017 Rationale Mechanistic target of rapamycin inhibitors reduce loss of lung function in lymphangioleiomyomatosis (LAM), although their benefit varies between individuals.
Janet Bee +9 more
core +2 more sources
Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase [PDF]
, 2015 & Sons Ltd and Foundation for Cellular and Molecular Medicine. Lymphangioleiomyomatosis (LAM) is associated with dysfunction of the tuberous sclerosis complex (TSC) leading to enhanced cell proliferation and migration.
Black, JL +5 more
core +1 more source
Highlights of the Brazilian Thoracic Association guidelines for interstitial lung diseases [PDF]
, 2012 Interstitial lung diseases (ILDs) are heterogeneous disorders, involving a large number of conditions, the approach to which continues to pose an enormous challenge for pulmonologists.
Aidé, Miguel Abidon +24 more
core +3 more sources
Frontiers in Medicine, 2021 Background: Lymphangioleiomyomatosis (LAM) is a rare systemic disease that generally leads to a progressive decline in pulmonary function. Experience, especially from the Asian population, including combined drug therapy before and after lung ...
Ji Zhang +13 more
doaj +1 more source
Osteoprotegerin Contributes to the Metastatic Potential of Cells with a Dysfunctional TSC2 Tumor-Suppressor Gene [PDF]
, 1974 In addition to its effects on bone metabolism, osteoprotegerin (OPG), a soluble member of the tumor necrosis factor family of receptors, promotes smooth muscle cell proliferation and migration and may act as a survival factor for tumor cells.
Steagall, Wendy K. +6 more
core +1 more source
Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. [PDF]
, 2014 BackgroundBevacizumab and temsirolimus are active agents in gynecologic tumors. Temsirolimus attenuates upregulation of HIF-1α levels, a resistance mechanism for antiangiogenics, and targets the PI3-kinase/AKT/mTOR axis, commonly aberrant in these tumors.
Falchook, Gerald S +9 more
core +3 more sources
Annals of Thoracic Medicine, 2014 Lymphangioleiomyomatosis (LAM) is a rare disease that leads to airways and lymphatic channels obstruction due to abnormal smooth muscle proliferation. It presents with dyspnea, pneumothorax or chylothorax.
Mohammed Hussein +3 more
doaj +1 more source
Retroperitoneal Lympathic Malformations as First Presentation of Lymphangioleiomyomatosis
Journal of the Belgian Society of Radiology, 2021 Teaching Point: This case highlights the extrapulmonary lymphatic abnormalities that may be associated with pulmonary lymphangioleiomyomatosis.
Christine Lenfant, Cristina Anca Dragean
doaj +1 more source